- Home
- KZR vs RANI Comparison
KZR vs RANI Comparison
Compare KZR & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- RANI
- Stock Information
- Founded
- KZR 2015
- RANI 2012
- Country
- KZR United States
- RANI United States
- Employees
- KZR N/A
- RANI N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- KZR Health Care
- RANI Health Care
- Exchange
- KZR Nasdaq
- RANI Nasdaq
- Market Cap
- KZR 29.7M
- RANI 24.2M
- IPO Year
- KZR 2018
- RANI 2021
- Fundamental
- Price
- KZR $6.21
- RANI $1.95
- Analyst Decision
- KZR Hold
- RANI Strong Buy
- Analyst Count
- KZR 4
- RANI 6
- Target Price
- KZR $6.00
- RANI $8.67
- AVG Volume (30 Days)
- KZR 464.9K
- RANI 53.8M
- Earning Date
- KZR 11-07-2025
- RANI 11-06-2025
- Dividend Yield
- KZR N/A
- RANI N/A
- EPS Growth
- KZR N/A
- RANI N/A
- EPS
- KZR N/A
- RANI N/A
- Revenue
- KZR N/A
- RANI $1,200,000.00
- Revenue This Year
- KZR N/A
- RANI N/A
- Revenue Next Year
- KZR N/A
- RANI N/A
- P/E Ratio
- KZR N/A
- RANI N/A
- Revenue Growth
- KZR N/A
- RANI N/A
- 52 Week Low
- KZR $3.53
- RANI $0.39
- 52 Week High
- KZR $7.65
- RANI $3.87
- Technical
- Relative Strength Index (RSI)
- KZR 67.84
- RANI 54.49
- Support Level
- KZR $5.99
- RANI $1.77
- Resistance Level
- KZR $6.23
- RANI $2.10
- Average True Range (ATR)
- KZR 0.15
- RANI 0.37
- MACD
- KZR -0.08
- RANI -0.06
- Stochastic Oscillator
- KZR 44.44
- RANI 42.56
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.